Harrow, Inc. (HROW): who owns it and who trades it
As of Nov 16, 2026, HROW insiders reported 7 open-market sales worth $9.6M and 4 purchases worth $469K in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Opaleye Management Inc. (10% owner), with $9.2M. 3 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Harrow
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns HROW
223 funds and institutions reported HROW shares worth $961M at the end of Q2 2026, about 63% of the company. The largest holder is BlackRock, Inc. with 7.4%.
Funds and institutions (13F) 63%Everyone else 37%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 2.74M | 7.36% | $116M | +7% |
| Opaleye Management Inc. | 2.40M | 6.45% | $102M | -15% |
| California State Teachers Retirement System | 1.62M | 4.34% | $38M | +4039% |
| Private Capital Management, LLC | 1.60M | 4.29% | $67.9M | +2% |
| Vanguard Capital Management LLC | 1.42M | 3.81% | $60.2M | +1% |
| Deep Track Capital, LP | 969,000 | 2.60% | $41.2M | – |
| State Street Corp | 939,888 | 2.52% | $39.9M | +10% |
| Geode Capital Management, LLC | 905,560 | 2.43% | $38.5M | +6% |
| Bamco Inc | 809,350 | 2.17% | $34.4M | – |
| Dimensional Fund Advisors LP | 667,036 | 1.79% | $28.3M | +15% |
| Jupiter Topco LLC | 579,127 | 1.56% | $24.6M | – |
| Divisadero Street Capital Management, LP | 439,155 | 1.18% | $18.7M | – |
| Rice Hall James & Associates, LLC | 387,545 | 1.04% | $16.5M | +5% |
| Marshall Wace, LLP | 369,435 | 0.99% | $15.7M | -43% |
| Citadel Advisors LLC | 359,874 | 0.97% | $15.3M | +63% |
| Northern Trust Corp | 323,206 | 0.87% | $13.7M | +9% |
| Schonfeld Strategic Advisors LLC | 319,625 | 0.86% | $13.6M | – |
| Vanguard Portfolio Management LLC | 318,610 | 0.86% | $13.5M | +10% |
| Charles Schwab Investment Management Inc | 273,696 | 0.74% | $11.6M | +1% |
| Sixth Street Partners Management Company, L.P. | 273,696 | 0.74% | $11.6M | – |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, HROW insiders reported $469K of open-market purchases and $9.6M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Aug 14, 2026 | Amir Shojaei | CHIEF SCIENTIFIC OFFICER | Sale | 11,250 | $40.00 | $450K | Form 4 |
| May 18, 2026 | Adrienne L Graves | Director | Purchase | 1,000 | $31.07 | $31.1K | Form 4 |
| May 18, 2026 | Lauren P Silvernail | Director | Purchase | 1,000 | $31.00 | $31K | Form 4 |
| May 14, 2026 | Mark L Baum | CEO | Purchase | 10,000 | $30.20 | $302K | Form 4 |
| May 14, 2026 | Andrew R. Boll | CFO | Purchase | 3,500 | $29.90 | $105K | Form 4 |
| Mar 4, 2026 | Opaleye Management Inc. | 10% owner | Sale | 134,000 | $39.67 | $5.3M | Form 4 |
| Mar 4, 2026 | Opaleye Management Inc. | 10% owner | Sale | 4,263 | $39.67 | $169K | Form 4 |
| Mar 3, 2026 | Opaleye Management Inc. | 10% owner | Sale | 1,309 | $39.15 | $51.2K | Form 4 |
| Mar 3, 2026 | Opaleye Management Inc. | 10% owner | Sale | 59,000 | $39.15 | $2.3M | Form 4 |
| Feb 27, 2026 | Opaleye Management Inc. | 10% owner | Sale | 5,000 | $54.18 | $271K | Form 4 |
| Jan 6, 2026 | Opaleye Management Inc. | 10% owner | Sale | 20,000 | $53.35 | $1.1M | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Opaleye Management Inc. | 10% owner | – | $9.2M | Mar 4, 2026 |
| Amir Shojaei | CHIEF SCIENTIFIC OFFICER | – | $450K | Aug 14, 2026 |
| Mark L Baum | CHIEF EXECUTIVE OFFICER, Director | $302K | – | May 14, 2026 |
| Andrew R. Boll | PRESIDENT AND CFO | $105K | – | May 14, 2026 |
| Adrienne L Graves | Director | $31.1K | – | May 18, 2026 |
| Lauren P Silvernail | Director | $31K | – | May 18, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
HROW short interest
High short interest. 18.9% of HROW shares are sold short: about 1 share in 5. Over the last 12 reports the number of shares short went up 9%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 7.09M HROW shares were sold short, 18.9% of the shares outstanding, down 5.1% from the report before. At the average daily volume of 502,072 shares, buying them all back would take about 14.1 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 7.09M | 18.92% | -5% | 502,072 | 14.1 |
| Oct 15, 2026 | 7.47M | 19.94% | -4% | 665,535 | 11.2 |
| Sep 30, 2026 | 7.76M | 20.71% | +4% | 626,927 | 12.4 |
| Sep 15, 2026 | 7.49M | 19.98% | +10% | 477,523 | 15.7 |
| Aug 31, 2026 | 6.78M | 18.08% | +7% | 495,125 | 13.7 |
| Aug 14, 2026 | 6.36M | 16.96% | -6% | 616,836 | 10.3 |
| Jul 31, 2026 | 6.78M | 18.22% | -1% | 576,307 | 11.8 |
| Jul 15, 2026 | 6.84M | 18.38% | -4% | 542,217 | 12.6 |
| Jun 30, 2026 | 7.15M | 19.20% | -2% | 922,049 | 7.8 |
| Jun 15, 2026 | 7.31M | 19.63% | +9% | 737,703 | 9.9 |
| May 29, 2026 | 6.69M | 17.97% | +3% | 795,590 | 8.4 |
| May 15, 2026 | 6.49M | 17.44% | +0% | 1.25M | 5.2 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Harrow company events
Harrow filed 15 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 9, 2026.
- Nov 9, 2026ResultsReleased financial results. Filing
- Oct 5, 2026DealPursuant to the Purchase Agreement, the Company agreed to acquire rights to TYRVAYA in all countries of the world other than Japan. Filing
- Sep 4, 2026LeadershipRandall E. Pollard ceased serving as Chief Accounting Officer and principal accounting officer of Harrow, Inc. Filing
- Aug 10, 2026ResultsReleased financial results. Filing
- Aug 6, 2026AgreementHarrow, Inc. entered into an Asset Purchase Agreement with Viatris Inc., pursuant to which the Company agreed to acquire the global rights to TYRVAYA® (varenicline solution) nasal spray 0.03 mg, a cholinergic agonist indicated for the treatment of the signs and symptoms of dry eye disease. Filing
- Jun 22, 2026VoteReported shareholder vote results. Filing
- Jun 3, 2026AnnouncementShared information with investors. Filing
- May 11, 2026ResultsReleased financial results. Filing
- Mar 27, 2026AgreementHarrow, Inc. entered into a purchase agreement, dated March 24, 2026 with BTIG, LLC, as representative of the several initial purchasers named therein, in connection with its offer and sale of $50.0 million of additional 8.625% Senior Notes due 2030. Filing
- Mar 24, 2026AnnouncementHarrow, Inc. issued a press release announcing the pricing of its offering of $50.0 million of additional 8.625% Senior Notes due 2030 in a private offering to persons reasonably believed to be “qualified institutional buyers” in the United States, as defined in Rule 144A under the Securities Act… Filing
- Mar 24, 2026AnnouncementHarrow, Inc. issued a press release to announce the launch of its offer to sell $50.0 million of additional 8.625% Senior Notes due 2030 in a private offering to persons reasonably believed to be “qualified institutional buyers” in the United States, as defined in Rule 144A under the Securities Act… Filing
- Mar 10, 2026AnnouncementShared information with investors. Filing
- Mar 2, 2026ResultsReleased financial results. Filing
- Feb 2, 2026LeadershipThe Company appointed Patrick W. Sullivan, age 50, as Chief Commercial Officer of the Company, effective immediately. Filing
- Nov 18, 2025DealHarrow, Inc. completed the previously announced acquisition of Melt Pharmaceuticals, Inc. pursuant to the Agreement and Plan of Merger, dated September 24, 2025, by and among the Company, Harrow Acquisition Sub, Inc., Melt, and the stockholder representative. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Harrow financials
Famous investors that hold HROW
3 of the 50 well-known investors we track reported holding HROW in their latest 13F filing. The largest position is Ken Griffin's, worth $16M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 520,863 | $16M | 0.0% | +45% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 28,517 | $878K | 0.0% | -36% |
| George Soros · Soros Fund Management | Q3 2026 | 20,213 | $623K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named HROW in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 12, 2026 | Daniel Kaufman | 13G/A | 7.7% |
| Nov 12, 2026 | Daniel Kaufman | 13G/A | 7.7% |
| Nov 6, 2026 | Opaleye Management Inc. | 13G/A | 5.6% |
| Nov 6, 2026 | Opaleye Management Inc. | 13G/A | 5.6% |
| Oct 27, 2026 | BlackRock, Inc. | 13G/A | 7.4% |
| Oct 27, 2026 | BlackRock, Inc. | 13G/A | 7.4% |
Questions about Harrow, Inc. (HROW) stock
Who owns the most HROW stock?
The largest reported owner of Harrow, Inc. (HROW) is BlackRock, Inc., with 7.4% of the company. In total, 223 funds and institutions reported holding HROW at the end of Q2 2026, together about 63% of the shares. See the largest owners.
Are HROW insiders buying or selling?
In the last 12 months, HROW insiders reported 4 open-market purchases worth $469K and 7 sales worth $9.6M. The latest trade was on Aug 14, 2026. See every trade.
What is the short interest in HROW?
As of Oct 30, 2026, 7.09M HROW shares were sold short, 18.9% of the shares outstanding, down 5.1% from the report before. At the average daily volume of 502,072 shares, buying them all back would take about 14.1 trading days (days to cover). See the history.
Which famous investors hold HROW?
3 of the 50 well-known investors we track reported HROW in their latest 13F filing, including Ken Griffin, Jim Simons, George Soros. The largest position is worth $16M. See all holders.
Executive pay
Harrow's chief executive was paid a total of $23.6M for the year ended Dec 31, 2025, up 1638% from $1.4M the year before. In the last 12 months, Harrow's executives and directors bought $469K of stock on the open market and sold $450K.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.